...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients.
【24h】

Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients.

机译:移植前肝功能影响同种异体造血干细胞移植的结果:一项针对455例患者的研究。

获取原文
获取原文并翻译 | 示例

摘要

Liver dysfunction is frequent before allogeneic stem cell transplantation (allo-SCT). However, its characteristics and impact on transplantation outcomes are uncertain, especially in the reduced-intensity conditioning (RIC) setting. We analyzed 455 patients receiving an allo-SCT in 3 Spanish centers. Pretransplantation aspartate aminotransferase (AST), alanine aminotransaminase (ALT), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (AP), total bilirubin, and international normalized ratio were analyzed. Pretransplantation liver function test abnormalities were found in 94 (22%) patients. The most frequent cause of pretransplantation liver dysfunction was isolated elevation of GGT/AP (n = 49, 53%). Patients with high bilirubin levels before allo-SCT showed higher 4-year nonrelapse mortality (4y-NRM) (hazard ratio [HR] 2 [95% confidence interval [CI] 1.1-3.8] P = .02) and patients with high GGT levels showed higher 100-day NRM and lower 4-year overall survival (OS) (HR 3.4 [95% CI 1.8-6.7] P < .001, and HR 2 [95% CI 1.4-3], P = .001), respectively. High levels of transaminases did not influence on survival or mortality. In conclusion, hepatic dysfunction before allo-SCT is frequent and has an impact on transplantation outcomes. The best indicator of liver dysfunction still has to be determined.
机译:异基因干细胞移植(allo-SCT)之前,肝功能障碍很常见。但是,它的特性和对移植结果的影响尚不确定,尤其是在降低强度调节(RIC)设置中。我们分析了西班牙3个中心的455名接受同种SCT的患者。分析了移植前的天冬氨酸转氨酶(AST),丙氨酸转氨酶(ALT),γ-谷氨酰转肽酶(GGT),碱性磷酸酶(AP),总胆红素和国际标准化比率。 94名(22%)患者发现了移植前肝功能检查异常。移植前肝功能障碍的最常见原因是GGT / AP升高(n = 49,53%)。异基因SCT前胆红素水平高的患者显示出较高的4年非复发死亡率(4y-NRM)(危险比[HR] 2 [95%置信区间[CI] 1.1-3.8] P = .02)和GGT高的患者水平显示较高的100天NRM和较低的4年总生存(OS)(HR 3.4 [95%CI 1.8-6.7] P <.001,HR 2 [95%CI 1.4-3],P = .001) , 分别。高水平的转氨酶不会影响生存或死亡率。总之,异基因SCT之前的肝功能障碍很常见,并且对移植结果有影响。肝功能障碍的最佳指标仍需确定。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号